Saturday, April 20, 2024 9:56:57 PM
Leronlimab was proven being effective many times , much more effective , imo , then some of the toxic approved drugs , and in contrary without one serious side effect .
But then Dr Jeffrey Murray working at the time in FDA , didn’t talk in his emails about other companies i as he did about CYDY …
“ I hate them ..”
Another FDA employee posted in her email , it was Susan S ( I dont remember her last name )
So she said .
— you know this drug is an immunosuppressant ,
Wow , who they have working there .
No, it is not an immunosupressant , it is an immune modulator .
FDA , know what you are talking about !!!
Leronlimab has a great results in following studies ..
—-Phase 3 pivotal study for combo HIV , finished with 81% efficacy , and not one serious side effect. When at the time 2 other approved drugs were ,maraviroc with 45% , and Ibalizumab with 43%
—- CD12 study in critical Covid showed ,
82% mortality benefit ABOVE any drug in the world , when leronlimab was in the system ..
—-small study in cancers showed really positive results …
—-as also in Nash …
-—Long Covid study was a big success , it showed that some patients immune system is hyperactive , but many are immunosuppressed , leronlimab worked as a great immunemodulator in both ..
This study was peer reviewed and published by Dr Otto Yang from UCLA..
Yes , leronlimab seems to be a great drug , much better then many approved for us toxic , doing nothing , or minimum good drugs !!
All imo
GLTA longs
But then Dr Jeffrey Murray working at the time in FDA , didn’t talk in his emails about other companies i as he did about CYDY …
“ I hate them ..”
Another FDA employee posted in her email , it was Susan S ( I dont remember her last name )
So she said .
— you know this drug is an immunosuppressant ,
Wow , who they have working there .
No, it is not an immunosupressant , it is an immune modulator .
FDA , know what you are talking about !!!
Leronlimab has a great results in following studies ..
—-Phase 3 pivotal study for combo HIV , finished with 81% efficacy , and not one serious side effect. When at the time 2 other approved drugs were ,maraviroc with 45% , and Ibalizumab with 43%
—- CD12 study in critical Covid showed ,
82% mortality benefit ABOVE any drug in the world , when leronlimab was in the system ..
—-small study in cancers showed really positive results …
—-as also in Nash …
-—Long Covid study was a big success , it showed that some patients immune system is hyperactive , but many are immunosuppressed , leronlimab worked as a great immunemodulator in both ..
This study was peer reviewed and published by Dr Otto Yang from UCLA..
Yes , leronlimab seems to be a great drug , much better then many approved for us toxic , doing nothing , or minimum good drugs !!
All imo
GLTA longs
Bullish
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
